Idea principal
Pooling 3 studies with 3226 people with non-alcoholic fatty liver disease, sarcopenia was associated with steatohepatitis (OR 2.35, 95% CI 1.45-3.81) and advanced liver fibrosis (OR 2.41, 95% CI 1.94-2.98). Only three studies were available, and they are cross-sectional associations that cannot show which condition comes first.
Study design
Revisión de evidencia
Reading basis
Published abstract
Reading focus
Design & applicability
Esta explicación editorial está disponible en inglés, chino simplificado y chino tradicional. Esta interfaz muestra la lectura en inglés.
Pregunta de investigación
Sarcopenia, the loss of muscle mass and strength, has been linked to fatty liver disease, but the evidence is scattered. The authors pooled published studies to measure how strongly sarcopenia relates to the biopsy-based severity of non-alcoholic fatty liver disease.
Población y método
Meta-analysis. PubMed, the Cochrane Library and EMBASE were searched until August 2017 for studies of sarcopenia and steatohepatitis or advanced liver fibrosis in non-alcoholic fatty liver disease. Three articles (3226 individuals) were included; 2 examined steatohepatitis and all 3 examined advanced fibrosis. Pooled odds ratios were estimated with fixed-effects models, and sensitivity analyses excluded each study in turn.
Resultados
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Sarcopenia was associated with steatohepatitis, with a pooled odds ratio of 2.35 (95% CI 1.45-3.81), based on 2 studies.
- 2Sarcopenia was associated with advanced liver fibrosis, with a pooled odds ratio of 2.41 (95% CI 1.94-2.98), based on all 3 studies.
- 3No significant heterogeneity was detected in any comparison, and the results stayed essentially unchanged after excluding any one study.
- 4The authors suggest that future work should test whether sarcopenia plays a role in how the liver disease develops, which could have therapeutic implications.
Límites e incertidumbre
- 1Only 3 studies were pooled, and just 2 contributed to the steatohepatitis result, so the estimates rest on very few data sources.
- 2An odds ratio from such studies shows association at one point in time; sarcopenia could result from liver disease rather than contribute to it.
- 3The abstract does not say how sarcopenia was defined in each study or what other factors were adjusted for.
- 4This reading is based on the abstract only.
Relevancia práctica
People with fatty liver disease who also have low muscle mass tended to have more advanced liver disease. That makes keeping muscle through activity and adequate nutrition a sensible goal, but this review does not show that building muscle improves the liver. Questions about liver disease or muscle loss belong with your clinician.
Tus datos
Muscle mass is not directly measured by most wearables. You can follow related habits such as weekly strength sessions in a training log, and body composition from a scale or scan using the same device and conditions each time. Liver status needs medical testing.
Cómo interpretar la evidencia
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Resumen estructurado de los autores English
El resumen original en inglés se reproduce con atribución bajo la licencia indicada. Es una fuente, no una interpretación de MoveVitals. El análisis preparado figura arriba; verifica los resultados importantes en la fuente.
Background
Several studies have emerged indicating that sarcopenia is associated with nonalcoholic fatty liver disease, we aimed to systematically review and quantify the association between sacropenia and the histological severity of nonalcoholic fatty liver disease.
Methods
Pubmed, the Cochrane Library and EMBASE were searched (until August 2017) for studies examining the relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in nonalcoholic fatty liver disease. Pooled odds ratios were estimated by fixed effects models.
Results
Three articles met our inclusion criteria, with a total of 3226 individuals. Two of the studies examined the association between sacropenia and steatohepatitis, a significant association was documented between sarcopenia and steatohepatitis (OR = 2.35, 95%CI 1.45, 3.81). All of the three studies assessed the association between sacropenia and advanced liver fibrosis, a significant association between sarcopenia and advanced liver fibrosis (OR = 2.41, 95%CI 1.94, 2.98). No significant heterogeneity was detected among studies in all comparisons. These results remained essentially unchanged after excluding any of the studies in the sensitivity analysis.
Conclusions
Sarcopenia in patients with nonalcoholic fatty liver disease is associated with a higher likelihood of having steatohepatitis or advanced liver fibrosis. Demonstration of the role of sarcopenia in nonalcoholic fatty liver disease development in future studies could have important therapeutic implications.
Fuentes y atribución
Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis.
Yu R, Shi Q, Liu L, Chen L.
BMC gastroenterology · 2018-04-19
DOI: 10.1186/s12876-018-0776-0 ↗PubMed · 29673321 ↗Europe PMC · Licencia registrada: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interpretación editorial de MoveVitals · contenido educativo · sin revisión clínica individual registrada
Fuentes verificadas 2026-11-01
Guías prácticas
Leer en contexto
ACSM review of 137 reviews: resistance training works, and few programme details matter
The American College of Sports Medicine pooled 137 systematic reviews (over 30,000 healthy adults) and concluded that resistance training beats no exercise for strength, muscle size, power, endurance and several function tests. Few programme details changed results consistently: heavier loads (80% or more of one-repetition maximum) and 2 to 3 sets favoured strength, and at least 10 sets a week favoured muscle size, while training to failure, exercise type and periodization did not. It summarises reviews rather than new trials, gives no pooled effect sizes, and drew mostly on untrained adults and overlapping source trials.
Medicine & Science in Sports & Exercise
Nearly every resistance training plan beat no exercise; heavy loads led for strength
In a network meta-analysis of randomised trials in healthy adults (178 studies and 5097 people for strength, 119 studies and 3364 people for muscle size), nearly all resistance training prescriptions beat no exercise. Higher-load, multiset, thrice-weekly training ranked best for strength (standardised mean difference 1.60, 95% credible interval 1.38 to 1.82) and higher-load, multiset, twice-weekly training for muscle size (0.66, 0.47 to 0.85). Most prescriptions could not be statistically separated from each other (the 95% interval contained zero in 91% of the comparisons between them) and risk of bias was moderate to high, so the rankings are tentative.
British Journal of Sports Medicine
Muscle-strengthening linked to lower risk of death, heart disease, cancer and diabetes
Pooling 16 prospective cohort studies of adults, people who did muscle-strengthening activity had a 15% lower risk of all-cause mortality (RR 0.85, 95% CI 0.79 to 0.93) and a 17% lower risk of both cardiovascular disease and diabetes (RR 0.83 for each) than people who did none. The pooled mortality curve was lowest at about 40 min/week (RR 0.83), but whether larger amounts help or hurt is unclear. All of this is observational, from mostly US self-reported data, and the authors rated the certainty of evidence as very low for most outcomes.
British Journal of Sports Medicine
Protein supplements and weight training: small extra gains, smaller in older adults
Pooling 49 randomised trials with 1,863 healthy adults who did resistance training for at least 6 weeks, protein supplements added 0.30 kg of fat-free mass (95% CI 0.09 to 0.52) and 2.49 kg of one-repetition-maximum strength (0.64 to 4.33) on top of training alone. These gains were small next to the effect of training itself, were weaker with older age, and the suggested plateau near 1.6 g/kg/day was not statistically significant (p=0.079). One author has received funding from the US National Dairy Council, which supported trials in the analysis.
British Journal of Sports Medicine

